TP53 and nonpapillary renal cell carcinoma: Experimental genetic manipulation of other commonly mutated ccRCC genes, such as PBRM1, BAP1, SETD2, KDM5C, TP53, and other DNA repair genes, in cell culture models could also be conducted to investigate potential ATRi therapy–based modifying effects of these genes or to determine whether specific mutations may lead to sensitivities to other forms of pharmacological manipulation of DNA repair networks.